Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hong-Yun Xing"'
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Commensal bacteria and other microorganisms that reside in the human body are closely associated with the development and treatment of cancers. Recently, tumor microbiome (TM) has been identified in a variety of cancers such as pancreatic, lung, and
Externí odkaz:
https://doaj.org/article/a9870c1bc148407195dd0f83b33ad82e
Autor:
Hong Yun Xing
Publikováno v:
Advanced Materials Research. :2567-2570
The principle of no-negative-pressure variable frequency water-supply system and the current situation and characteristics of the water consumption in campus are analyzed, and at the same time, water-supply design precautions are put forward. With a
Publikováno v:
International Journal of Laboratory Hematology. 33:176-181
Summary Introduction: We investigated the second-generation tyrosine kinase inhibitors, dasatinib and nilotinib, for their potential to overcome resistance in the imatinib-resistant K562 cell line, and evaluated whether rapamycin, an mammalian target
Publikováno v:
Blood cells, moleculesdiseases. 53(1-2)
Transcription factor stem cell leukemia (SCL), also known as the T-cell acute lymphocytic leukemia 1 (TAL1), plays a key role in the regulation of hematopoiesis, but the molecular mechanisms are not well understood. The aim of the present study is to
Autor:
Juan, Lin, Hong-Yun, Xing, Yu-Ping, Gong, Xi, Yang, Yong, Guo, Qing-Qing, Shan, Rui-Qing, Zhou
Publikováno v:
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition. 43(5)
To investigate the contribution of multidrug-resistant gene MDR1 to development of imatinib-resistance in Ph(+) acute lymphoblastic leukemia cell line SUP-B15/RI.RT-PCR was used to examine MDR1 mRNA levels, cytotoxic effects of imatinib (IM), daunoru
Publikováno v:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 32(5)
Publikováno v:
Leukemia research. 36(4)
In this study, we established an imatinib resistant Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15/RI in vitro and studied the mechanism of imatinib resistance. Our results showed that the BCR-ABL1 fusion gene and the mdr1 gene were 6.1 tim
Publikováno v:
Blood. 116:2135-2135
Abstract 2135 Objective To establish an imatinib resistant Bcr-Abl positive acute lymphoblastic leukemia (ALL) cell line in vitro and to study imatibin resistance in Ph+ ALL. The reversal of the imatinib resistance by rapamycin, the second generation
Publikováno v:
International Journal of Cardiology. 137:S36